SOURCE: Vernalis PLC

August 20, 2015 02:00 ET

Vernalis plc Completes Investment in Its NCE Development Pipeline

WINNERSH, UNITED KINGDOM--(Marketwired - Aug 20, 2015) - Vernalis plc today announces the results from a Phase II proof-of-concept (POC) study of V158866, its fatty acid amide hydrolase (FAAH) inhibitor, which is being investigated as a treatment for neuropathic pain as a result of spinal cord injury.

In the randomised, double-blind, placebo-controlled, two-period cross-over study, although dosing of V158866 resulted in elevated endocannabinoid levels, on an intent-to-treat basis the study failed to meet its pain reduction primary endpoint. Treatment with V158866 did however show a trend towards efficacy on a per protocol basis (p=0.054) and was generally well tolerated.

Consistent with its strategy of becoming a commercial business, Vernalis is not planning to make any further investment in this programme and will seek to realise its potential value through partnering. A previous Phase I study provided encouraging data in evaluating the safety, tolerability and pharmacokinetic and pharmacodynamic effects of the compound.

Ian Garland, CEO of Vernalis commented "The goal of this study was to identify a therapeutic setting for this programme. Its completion ends the investment in our NCE pipeline and we aim to partner the remaining unpartnered programmes to realise value where possible. The key focus of the organisation remains the transition of Vernalis to a commercial company, with the forthcoming launch of Tuzistra™ XR, our extended release cough cold product for the US prescription market, which is progressing as planned".

Notes to Editors
About Vernalis
Vernalis is a revenue generating, commercial stage pharmaceutical company with significant expertise in drug development. The Group has two approved products; Tuzistra™ XR targeting the US prescription cough cold market and, frovatriptan for the acute treatment of migraine. It has an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as eight programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including AKP, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier Taisho and Tris.

For further information about Vernalis, please visit www.vernalis.com.

Contact Information

  • Enquiries:

    Vernalis plc:
    Ian Garland
    Chief Executive Officer
    David Mackney
    Chief Financial Officer
    +44 (0) 118 938 0015

    Canaccord Genuity Limited (Nominated Adviser):
    +44 (0) 20 7523 8000
    Dr Julian Feneley
    Laura White
    Henry Fitzgerald-O'Connor

    Shore Capital (Joint Broker):
    +44 (0) 20 7408 4090
    Bidhi Bhoma
    Toby Gibbs

    FTI Consulting:
    +44 (0) 20 3727 1000
    Ben Atwell
    Simon Conway